Pharma BD Deal Intelligence
Roche became the first Big Pharma into RNA editing at scale, committing over $3 billion for Shape Therapeutics' RNAfix and AAVid platforms in Alzheimer's and Parkinson's, though the mechanism still competes unproven against Beam, Verve, and Prime Medicine's DNA editing.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Site-directed RNA editing using endogenous ADAR enzymes recruited by short guide RNAs enables programmable adenosine-to-inosine edits in cellular transcripts…
Roche struck a strategic collaboration with Seattle-based Shape Therapeutics worth more than $3 billion to develop RNA editing therapeutics and AAV gene…
October 3, 2024: ShapeTX released two preprints detailing advances to its RNAfix RNA-editing platform, including the DeepREAD AI model for designing ADAR guide…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Roche entered a multi-year strategic collaboration and license agreement with Shape Therapeutics (ShapeTX) in August 2021 for next-generation AAV gene therapies and RNA editing therapeutics targeting Alzheimer's disease, Parkinson's disease and rare CNS diseases, pairing ShapeTX's RNAfix ADAR-recruiting RNA-editing platform and AAVid tissue-targeted capsid library with Roche's neuroscience and rare-disease development expertise. Total potential value exceeds $3B across upfront, research funding and development/regulatory/commercial milestones plus tiered royalties. On November 30, 2023 the partners expanded the alliance, with Roche adding a new target and initiating a program to develop a potential one-time therapy for an undisclosed disease affecting millions of people worldwide; the expansion carried a new initial milestone payment plus additional development, regulatory and sales milestones and tiered royalties. ShapeTX subsequently disclosed further AI-platform advances (DeepREAD guide-RNA design model and an enhanced U7 expression system) in October 2024.
6.2M US cases/yr · $5.5B Global Alzheimer's drug market 2021 (USD MM, pre-Leqembi) · 500000 US Alzheimer's incident cases annually
Alzheimer's disease (AD) is the most common form of dementia, affecting approximately 6.2 million Americans aged 65+ in 2021 per the Alzheimer's Association, with annual incidence of approximately 500,000 new cases and projected prevalence of 13.8 million by 2060. Direct US healthcare costs exceeded $355 billion in 2021. Parkinson's disease (PD) affects approximately 1 million Americans with annual incidence of approximately 60,000 new cases per the Parkinson's Foundation, with neurodegenerative loss of dopaminergic neurons in the substantia nigra producing tremor, rigidity, bradykinesia and postural instability. Both AD and PD have substantial unmet need: small-molecule symptomatic therapies (donepezil, rivastigmine, galantamine, memantine for AD; levodopa, dopamine agonists, MAO-B inhibitors for PD) provide modest symptomatic benefit but do not modify disease course. Aducanumab (Aduhelm, Biogen, anti-amyloid mAb) was approved June 2021 amid significant controversy over efficacy. Rare CNS disorders covered by the deal include monogenic neurogenetic conditions amenable to RNA editing or AAV gene replacement — examples include Rett syndrome (MECP2), Huntington's disease (HTT), spinal muscular atrophy (SMN1, served by Spinraza/Zolgensma/Evrysdi), giant axonal neuropathy, and pediatric neurogenetic ataxias. RNA editing offers reversible, dose-titratable single-base edits without genomic insertion risk, while AAV gene therapy enables one-time durable expression across CNS tissue.
The CNS therapeutics competitive landscape spans symptomatic small molecules, anti-amyloid biologics, RNA-targeting therapies, AAV gene therapy and emerging RNA editing platforms. Alzheimer's anti-amyloid: Aduhelm (aducanumab, Biogen/Eisai, approved June 2021 amid controversy), Leqembi (lecanemab, Eisai/Biogen, approved Jan 2023), donanemab (Eli Lilly), gantenerumab (Roche, failed Phase 3 GRADUATE Nov 2022). Anti-tau and other AD: Eli Lilly remternetug, AC Immune, Cassava sodium. PD: Biogen cinpanemab (failed Phase 2 anti-alpha-synuclein 2021), Roche prasinezumab (anti-alpha-synuclein, Phase 2), Voyager Therapeutics VY-AADC AAV gene therapy (Neurocrine partnership terminated 2020). RNA editing platforms: Shape Therapeutics (RNAfix ADAR-recruiting guide RNAs, RNA-Skip exon skipping, AAVid capsids), Korro Bio (OPERA ADAR platform), Wave Life Sciences (PN chemistry stereopure ASOs with editing extension), ProQR Therapeutics (Axiomer), Beam Therapeutics (DNA base editing — distinct mechanism but adjacent), Verve Therapeutics (in-vivo base editing for CV). AAV CNS gene therapy: Voyager Therapeutics, Sangamo (ZFP-TF), uniQure (AMT-130 Huntington), Ionis (anti-sense oligonucleotides — distinct mechanism), Sarepta. The Roche/Shape deal is the first major Big Pharma RNA editing partnership and is broader than Roche's prior Ionis ASO collaboration on tominersen (Huntington, paused 2021).
Roche added a new target to its 2021 RNA-editing/AAV gene-therapy collaboration with ShapeTX, initiating a program for a one-time therapy in an undisclosed disease affecting millions. New initial milestone payment plus dev/reg/sales milestones and tiered royalties; financial detail beyond structure undisclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Shape Therapeutics Inc. (this deal) | 2021 | $3.0B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2021 deals · Roche Holding AG deals · Neurology deals